According to a recent LinkedIn post from Phantom Neuro, the company plans to participate in The Montgomery Summit 2026 in Santa Monica, California, with a presentation scheduled for March 11, 2026. The post highlights that Founder & CEO Connor Glass is expected to present Phantom X, a minimally invasive neural interface designed to sit beneath the skin and decode muscle signals for prosthetic limb control.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Phantom X, supported by advanced AI, aims to provide more intuitive, high-accuracy and low-latency control of hand and wrist movements compared with conventional prosthesis control systems. By framing the technology as part of a “new era” in human–machine interaction, the content positions Phantom Neuro within the broader neurotechnology, biotech and AI-in-healthcare segments.
For investors, this planned conference appearance may indicate an effort to raise Phantom Neuro’s visibility among growth-focused investors and strategic partners attending The Montgomery Summit. Increased exposure at a high-profile investor and technology forum could support future fundraising, validate market interest in its neural interface platform and potentially accelerate commercial or clinical collaboration opportunities.
If Phantom X can ultimately translate its described performance into regulatory-cleared, scalable products, the company could tap into the growing prosthetics and human–machine interface markets. However, the post does not provide detail on regulatory status, commercialization timelines or revenue prospects, so the financial impact remains uncertain and dependent on execution, clinical outcomes and competitive dynamics in neurotech and AI-driven prosthetics.